Uniqure NV Form 4 insider transactions

uniQure N.V. CEO Matthew C. Kapusta reported transactions involving the sale of ordinary shares and the acquisition of shares through a stock option, all executed under a pre-arranged 10b5-1 trading plan.

Walid Abi-Saab, Chief Medical Officer at uniQure N.V., reported transactions involving the sale of ordinary shares and the acquisition of stock options under a pre-arranged trading plan.

uniQure N.V. Director Jack Kaye reports transactions involving the purchase and sale of ordinary shares, executed under a Rule 10b5-1 trading plan.

Walid Abi-Saab, Chief Medical Officer at uniQure N.V., reported the sale of 1,434 ordinary shares to cover tax withholding obligations upon the vesting of restricted share units.

uniQure N.V. CEO Matthew C. Kapusta executed a series of transactions involving the purchase and sale of company stock under a pre-arranged trading plan.

Director Madhavan Balachandran exercised options and sold 10,000 shares of uniQure N.V. under a Rule 10b5-1 trading plan.

Jeannette Potts, Chief Legal Officer of uniQure N.V., sold 5,237 ordinary shares to cover tax withholding obligations upon vesting of restricted share units.

Director David Meek acquired restricted share units and stock options while selling shares to cover tax obligations.

Director Robert Gut exercised stock options and sold shares of uniQure N.V. as part of a pre-arranged Rule 10b5-1 trading plan.

Kylie O'Keefe, Chief Customer & Strategy Officer at uniQure N.V., sold 15,936 shares to cover tax obligations upon the vesting of restricted share units.

Director Jeremy Springhorn received restricted share units and stock options while selling shares to cover tax obligations.

Director Leonard E. Post acquired restricted share units and exercised stock options, with a portion sold to cover tax obligations.

Director Jack Kaye acquired restricted share units and stock options while selling shares to cover tax obligations.

Director Rachelle Jacques acquired restricted share units and stock options while selling shares to cover tax obligations.

Director Madhavan Balachandran acquired restricted share units and stock options while selling shares to cover tax obligations.

Director Jack Kaye exercised options and sold 2,645 shares of uniQure N.V. under a pre-arranged Rule 10b5-1 trading plan.

uniQure's Chief Medical Officer, Walid Abi-Saab, executed a series of stock transactions under a pre-arranged 10b5-1 plan, selling a total of 45,000 ordinary shares.

uniQure N.V.'s CEO, Matthew C. Kapusta, reported the acquisition of restricted share units and stock options, alongside a non-discretionary sale of shares to cover tax withholdings.

uniQure's Chief Medical Officer, Walid Abi-Saab, received significant grants of restricted stock units and stock options, increasing his beneficial ownership.

uniQure N.V.'s Chief Legal Officer, Jeannette Potts, reported the acquisition of restricted share units and stock options, alongside a tax-related sale of shares.

uniQure N.V. CEO Matthew C. Kapusta sold 34,437 ordinary shares to cover estimated withholding taxes following restricted share unit vesting.

uniQure's Chief Financial Officer, Christian Klemt, sold 12,532 ordinary shares to cover tax liabilities upon the vesting of restricted share units.

uniQure's Chief Legal Officer sold 8,578 ordinary shares to cover tax obligations upon restricted share unit vesting.

uniQure N.V.'s Chief Medical Officer, Walid Abi-Saab, sold 1,660 ordinary shares to cover tax withholding obligations related to restricted share unit vesting.

uniQure N.V.'s CEO, Matthew C. Kapusta, sold 12,378 ordinary shares to cover estimated withholding taxes upon restricted share unit vesting.

uniQure N.V.'s Chief Financial Officer, Christian Klemt, sold 6,217 ordinary shares to cover tax liabilities from RSU vesting.

uniQure N.V. Director Robert Gut exercised stock options and subsequently sold a portion of his ordinary shares under a pre-arranged 10b5-1 plan.

uniQure N.V. Director Jack Kaye exercised stock options and subsequently sold 6,390 ordinary shares on January 9, 2026, under a pre-arranged 10b5-1 plan.

uniQure Director Robert Gut executed a pre-planned sale of ordinary shares, following the exercise of stock options, as disclosed in a recent Form 4 filing.

uniQure N.V. Director Jack Kaye executed pre-planned transactions, exercising stock options and subsequently selling 38,810 ordinary shares for a significant profit.